BioWorld

Jan. 22, 2009

J&J Joins Enabling Technology Effort, Enlight Biosciences

Myriad Snares HIV Drug in $7M Deal with Panacos

Tragara Pays $112M to Jointly Develop S*BIO Compound

Singapore-based S*BIO Pte. Ltd. has joined with San Diego-based Tragara Pharmaceuticals Inc. to develop a potential treatment for blood cancer and possibly solid tumors, in a deal worth up to $112.5 million. (BioWorld Today) Read More

Seattle Genetics Gets SPA to Study Lymphoma Drug

Today's news in brief

BioWorld

BioWorld briefs for Dec. 10, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 10, 2025.

Medline plans record-setting $5.37B IPO

BioWorld MedTech

Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...

US lawmakers demand that Kennedy be held accountable

BioWorld

As the systematic dismantling of the U.S. vaccine schedule escalates, the demands to hold Health and Human Services Secretary Robert Kennedy accountable are...

Epigenetic technology could eliminate misfolded prion proteins

BioWorld Science

The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...

BioWorld

Jan. 22, 2009

J&J Joins Enabling Technology Effort, Enlight Biosciences

Myriad Snares HIV Drug in $7M Deal with Panacos

Other News To Note

Clinic Roundup

Appointments And Advancements

Tragara Pays $112M to Jointly Develop S*BIO Compound

Seattle Genetics Gets SPA to Study Lymphoma Drug

Today's news in brief

Today's news in brief

Medline plans record-setting $5.37B IPO

US lawmakers demand that Kennedy be held accountable

Epigenetic technology could eliminate misfolded prion proteins